Alliancebernstein L.P. Nu Cana PLC Transaction History

Alliancebernstein L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 18, 2020	SELL	$5.55 - $8.48 $499,405 - $763,055	-89,983 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.95 - $10.71 $3.46 Million - $5.33 Million	-497,984 Reduced 84.7%	89,983 $651,000
Q2 2019 Aug 14, 2019	BUY	$9.74 - $17.45 $340,013 - $609,162	34,909 Added 6.31%	587,967 $6.1 Million
Q1 2019 May 14, 2019	BUY	$10.92 - $18.03 $216,139 - $356,867	19,793 Added 3.71%	553,058 $9.4 Million
Q4 2018 Feb 13, 2019	SELL	$13.0 - $22.57 $127,192 - $220,824	-9,784 Reduced 1.8%	533,265 $7.73 Million
Q3 2018 Nov 08, 2018	BUY	$20.12 - $26.86 $1.56 Million - $2.08 Million	77,519 Added 16.65%	543,049 $13.5 Million
Q2 2018 Aug 13, 2018	SELL	$19.0 - $29.84 $2.01 Million - $3.16 Million	-106,006 Reduced 18.55%	465,530 $8.85 Million
Q1 2018 May 14, 2018	SELL	$10.04 - $28.25 $3.4 Million - $9.57 Million	-338,822 Reduced 37.22%	571,536 $10.8 Million
Q4 2017 Feb 13, 2018	BUY	$10.0 - $18.72 $2.6 Million - $4.87 Million	260,358 Added 40.06%	910,358 $9.2 Million
Q3 2017 Nov 13, 2017	BUY	$16.15 - $18.37 $10.5 Million - $11.9 Million	650,000	650,000 $11.9 Million

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $59M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.